Effect of food on the pharmacokinetics of Olaparib after oral dosing of the capsule formulation in patients with advanced solid tumors.
dc.contributor.author | Rolfo, C | |
dc.contributor.author | Swaisland, H | |
dc.contributor.author | Leunen, K | |
dc.contributor.author | Rutten, A | |
dc.contributor.author | Soetekouw, P | |
dc.contributor.author | Slater, S | |
dc.contributor.author | Verheul, H | |
dc.contributor.author | Fielding, A | |
dc.contributor.author | So, K | |
dc.contributor.author | Bannister, W | |
dc.contributor.author | Dean, Emma J | |
dc.date.accessioned | 2015-08-12T14:24:22Z | en |
dc.date.available | 2015-08-12T14:24:22Z | en |
dc.date.issued | 2015-06 | en |
dc.identifier.citation | Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors. 2015, 32 (6):510-22 Adv Ther | en |
dc.identifier.issn | 1865-8652 | en |
dc.identifier.pmid | 26048134 | en |
dc.identifier.doi | 10.1007/s12325-015-0214-4 | en |
dc.identifier.uri | http://hdl.handle.net/10541/566201 | en |
dc.description.abstract | The oral, potent poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, is well tolerated at doses of ≤400 mg twice daily (BID) (administered as capsules), and has shown efficacy in patients with advanced BRCA-mutated ovarian and breast cancer. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Advances in therapy | en |
dc.title | Effect of food on the pharmacokinetics of Olaparib after oral dosing of the capsule formulation in patients with advanced solid tumors. | en |
dc.type | Article | en |
dc.contributor.department | Univ Antwerp Hosp, Dept Oncol, Early Clin Trials Unit, B-2650 Edegem, Belgium | en |
dc.identifier.journal | Advances in Therapy | en |
html.description.abstract | The oral, potent poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, is well tolerated at doses of ≤400 mg twice daily (BID) (administered as capsules), and has shown efficacy in patients with advanced BRCA-mutated ovarian and breast cancer. |